Immunogenicity of a peptide from a major neutralising determinant of the feline immunodeficiency virus surface glycoprotein

被引:14
作者
Rigby, MA
Mackay, N
Reid, G
Osborne, R
Neil, JC
Jarrett, O
机构
[1] MRC Retrovirus Research Laboratory, Department of Veterinary Pathology, University of Glasgow
[2] CRC Beatson Inst. for Cancer Res.
基金
英国医学研究理事会;
关键词
feline immunodeficiency virus; peptide vaccine;
D O I
10.1016/0264-410X(96)00060-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The third variable region (V3) of the feline immunodeficiency virus (FIV) surface glycoprotein is predicted to have similar physical properties to that of HIV and has been shown to contain immunodominant and neutralizing epitopes. Immunological characteristics of this region were investigated further using a peptide corresponding to the middle of the putative FIV V3 loop. The peptide was recognized in ELISA by sera from the majority of naturally FIV-infected cars, and absorbed a significant fraction of the virus neutralizing activity front a pool of sera of cats naturally infected with FIV, confirming the immunogenic nature of this region. A sheep immunized with an octameric form of the peptide (multiple antigenic peptide, MAP) in Freund's complete adjuvant generated neutralizing antibody to a higher titre than infected cats. However, immunization of cats with the same MAP in an acceptable adjuvant formulation (Quil A) induced antibody and cytotoxic T-cell responses to the immunizing peptides but only minimal neutralizing activity. These responses did not significantly alter the kinetics of infection or the proviral load after challenge with a homologous strain of FIV, compared with naive controls. While the potential efficacy of peptide vaccines to lentiviruses remains to be determined, this study shows that the immune response evoked may be highly dependent on the delivery and adjuvant regime used. Copyright (C) 1996 Elsevier Science Ltd.
引用
收藏
页码:1095 / 1102
页数:8
相关论文
共 42 条
[1]   SERUM NEUTRALIZATION OF FELINE IMMUNODEFICIENCY VIRUS IS MARKEDLY DEPENDENT ON PASSAGE HISTORY OF THE VIRUS AND HOST SYSTEM [J].
BALDINOTTI, F ;
MATTEUCCI, D ;
MAZZETTI, P ;
GIANNELLI, C ;
BANDECCHI, P ;
TOZZINI, F ;
BENDINELLI, M .
JOURNAL OF VIROLOGY, 1994, 68 (07) :4572-4579
[2]   PRIMARY STAGE OF FELINE IMMUNODEFICIENCY VIRUS-INFECTION - VIRAL DISSEMINATION AND CELLULAR TARGETS [J].
BEEBE, AM ;
DUA, N ;
FAITH, TG ;
MOORE, PF ;
PEDERSEN, NC ;
DANDEKAR, S .
JOURNAL OF VIROLOGY, 1994, 68 (05) :3080-3091
[3]   IMMUNOGENICITY OF SYNTHETIC HIV-1 GP120 V3-LOOP PEPTIDE-CONJUGATE IMMUNOGENS [J].
CONLEY, AJ ;
CONARD, P ;
BONDY, S ;
DOLAN, CA ;
HANNAH, J ;
LEANZA, WJ ;
MARBURG, S ;
RIVETNA, M ;
RUSIECKI, VK ;
SUGG, EE ;
VANMIDDLESWORTH, F ;
WARNE, SA ;
ULRICH, JT ;
RUDBACH, JA ;
TOLMAN, RL ;
EMINI, EA .
VACCINE, 1994, 12 (05) :445-451
[4]   ANTIBODY-RESPONSE IN CATS TO THE ENVELOPE PROTEINS OF FELINE IMMUNODEFICIENCY VIRUS - IDENTIFICATION OF AN IMMUNODOMINANT NEUTRALIZATION DOMAIN [J].
DERONDE, A ;
STAM, JG ;
BOERS, P ;
LANGEDIJK, H ;
MELOEN, R ;
HESSELINK, W ;
KELDERMANS, LCEJM ;
VANVLIET, A ;
VERSCHOOR, EJ ;
HORZINEK, MC ;
EGBERINK, HF .
VIROLOGY, 1994, 198 (01) :257-264
[5]   A COMPREHENSIVE SET OF SEQUENCE-ANALYSIS PROGRAMS FOR THE VAX [J].
DEVEREUX, J ;
HAEBERLI, P ;
SMITHIES, O .
NUCLEIC ACIDS RESEARCH, 1984, 12 (01) :387-395
[6]   PREVENTION OF HIV-1 INFECTION IN CHIMPANZEES BY GP120 V3 DOMAIN-SPECIFIC MONOCLONAL-ANTIBODY [J].
EMINI, EA ;
SCHLEIF, WA ;
NUNBERG, JH ;
CONLEY, AJ ;
EDA, Y ;
TOKIYOSHI, S ;
PUTNEY, SD ;
MATSUSHITA, S ;
COBB, KE ;
JETT, CM ;
EICHBERG, JW ;
MURTHY, KK .
NATURE, 1992, 355 (6362) :728-730
[7]  
FLYNN JN, 1995, IMMUNOLOGY, V85, P171
[8]   SIMIAN AND FELINE IMMUNODEFICIENCY VIRUSES - ANIMAL LENTIVIRUS MODELS FOR EVALUATION OF AIDS VACCINES AND ANTIVIRAL AGENTS [J].
GARDNER, MB .
ANTIVIRAL RESEARCH, 1991, 15 (04) :267-286
[9]   ANALYSIS OF ACCURACY AND IMPLICATIONS OF SIMPLE METHODS FOR PREDICTING SECONDARY STRUCTURE OF GLOBULAR PROTEINS [J].
GARNIER, J ;
OSGUTHORPE, DJ ;
ROBSON, B .
JOURNAL OF MOLECULAR BIOLOGY, 1978, 120 (01) :97-120
[10]  
*GEN COMP GROUP, 1991, PROGR MAN GCG PACK V